Guangzhou Lianrui Pharmaceutical Co. Ltd.

Main purpose: According to the relevant provisions of bioequivalence test, isavuconazole sulfate capsules (trade name: Kangxinbo®, specification: 100 mg) produced by SwissCo Services AG were selected as the reference preparation, and the test preparation isavuconazole sulfate capsules (specification: 100 mg) produced by Chongqing Boteng Pharmaceutical Co., Ltd. and licensed by Guangzhou Lianrui Pharmaceutical Co., Ltd. were conducted on fasting and postprandial human bioequivalence tests to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose: To observe the safety of oral administration of the test preparation isavuconazole sulfate capsules (specification: 100 mg) and the reference preparation isavuconazole sulfate capsules (trade name: Kangxinbo®, specification: 100 mg) by healthy volunteers.

The main purpose of the study is to study the pharmacokinetics of the test preparation, Asartan Potassium Tablets (Specification: 80 mg, produced by Guangzhou Lianrui Pharmaceutical Co., Ltd.) and the reference preparation, Asartan Potassium Tablets (trade name Edabi®, specification: 80 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. The secondary purpose of the study is to evaluate the safety of the test preparation, Asartan Potassium Tablets (Specification: 80 mg) and the reference preparation, Edabi® (Specification: 80 mg) in healthy subjects.

The primary objective was to compare the differences in the extent and rate of absorption of epinastine hydrochloride tablets (20 mg) provided by Guangzhou Lianrui Pharmaceutical Co., Ltd. and epinastine hydrochloride tablets (20 mg, trade name: Alesion ®) produced by Nippon Boehringer Ingelheim Co., Ltd. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. The secondary objective was to investigate the safety of the test preparation and the reference preparation in healthy volunteers. The secondary objective was to evaluate the safety of epinastine hydrochloride tablets (20 mg/tablet) provided by Guangzhou Lianrui Pharmaceutical Co., Ltd. under fasting and postprandial administration conditions.